- Home
- FRD vs HURA Comparison
FRD vs HURA Comparison
Compare FRD & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- HURA
- Stock Information
- Founded
- FRD 1965
- HURA 2009
- Country
- FRD United States
- HURA United States
- Employees
- FRD N/A
- HURA N/A
- Industry
- FRD Steel/Iron Ore
- HURA
- Sector
- FRD Industrials
- HURA
- Exchange
- FRD Nasdaq
- HURA Nasdaq
- Market Cap
- FRD 114.4M
- HURA 126.1M
- IPO Year
- FRD N/A
- HURA N/A
- Fundamental
- Price
- FRD $21.14
- HURA $2.61
- Analyst Decision
- FRD
- HURA Strong Buy
- Analyst Count
- FRD 0
- HURA 2
- Target Price
- FRD N/A
- HURA $11.50
- AVG Volume (30 Days)
- FRD 22.9K
- HURA 200.2K
- Earning Date
- FRD 11-11-2025
- HURA 11-13-2025
- Dividend Yield
- FRD 0.76%
- HURA N/A
- EPS Growth
- FRD N/A
- HURA N/A
- EPS
- FRD 1.21
- HURA N/A
- Revenue
- FRD $464,826,000.00
- HURA N/A
- Revenue This Year
- FRD N/A
- HURA N/A
- Revenue Next Year
- FRD N/A
- HURA N/A
- P/E Ratio
- FRD $16.75
- HURA N/A
- Revenue Growth
- FRD N/A
- HURA N/A
- 52 Week Low
- FRD $12.24
- HURA $1.80
- 52 Week High
- FRD $22.98
- HURA $8.40
- Technical
- Relative Strength Index (RSI)
- FRD 47.15
- HURA 45.68
- Support Level
- FRD $20.80
- HURA $2.38
- Resistance Level
- FRD $22.54
- HURA $2.66
- Average True Range (ATR)
- FRD 0.80
- HURA 0.12
- MACD
- FRD -0.39
- HURA 0.01
- Stochastic Oscillator
- FRD 16.54
- HURA 42.86
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.